

**2025 Inpatient - All sources other than urine  
(MHMH, APD, NLH)**



To obtain a sound statistical estimate of cumulative %S rates, organisms are included only when there are 30 or more unique patient isolates tested. Unless otherwise noted, data represents calendar year 2025.

	Number of Isolates	Penicillin	Ampicillin	Ox/Nafcillin	Ampicillin/Sulbactam	Piperacillin/Tazo	Cefazolin (first)	Cefuroxime (second)	CeFTAZidime (third)	CeTRTaxone (third)	Cefepime (fourth)	Meropenem	Daptomycin	Linezolid	Gentamicin	Tobramycin	Vancomycin	Clindamycin	Erythromycin	Metronidazole	Tetracycline	Minocycline	Trimethoprim-sulfa	Ciprofloxacin	Levofloxacin	
<b>GRAM POSITIVES</b>																										
<i>Staphylococcus aureus</i> - ALL <sup>1</sup>	782			65			65						100 <sup>2</sup>	100	99 <sup>3</sup>		100	77			87			83		
- <i>Staphylococcus aureus</i> - MSSA	506			100			100							100	99 <sup>3</sup>		100	79			92			95		
- <i>Staphylococcus aureus</i> - MRSA	276			0			0						100 <sup>2</sup>	100	99 <sup>3</sup>		100	70			76			58		
<i>Staphylococcus lugdunensis</i>	68			91			91							100	100 <sup>3</sup>		100	83			98			100		
<i>Staphylococcus coagulase negative sp.</i>	144			45			45							100	90 <sup>3</sup>		100	61			75 <sup>4</sup>			64		
<i>Streptococcus pneumoniae</i>	52	100								100							100		76					86		
- <i>Streptococcus pneumoniae</i> (meningitis)	52	80								92																
<i>Enterococcus faecium</i>	53	15	15				0 <sup>I</sup>	0 <sup>I</sup>	0 <sup>I</sup>	0 <sup>I</sup>	0 <sup>I</sup>		100 <sup>5</sup>	97	96 <sup>3,6</sup>		52	0 <sup>I</sup>						0 <sup>I</sup>		
<i>Enterococcus faecalis</i>	110	99	100				0 <sup>I</sup>	0 <sup>I</sup>	0 <sup>I</sup>	0 <sup>I</sup>	0 <sup>I</sup>			100	84 <sup>3,6</sup>		98	0 <sup>I</sup>						0 <sup>I</sup>		
<i>Streptococcus anginosus</i> grp (" <i>S. milleri</i> ")	61	96								100																100
<b>GRAM NEGATIVES</b>																										
<i>Haemophilus influenzae</i>	68		73 <sup>7</sup>																							
<i>Escherichia coli</i>	275		56		71	94 <sup>8</sup>	63			87	95 <sup>8</sup>	100			89									78	77	78
<i>Enterobacter cloacae</i> complex	82		0 <sup>I</sup>		0 <sup>I</sup>	70 <sup>8</sup>	0 <sup>I</sup>			61 <sup>9</sup>	95 <sup>10</sup>	100			97									90	91	87
<i>Klebsiella oxytoca</i>	35		0 <sup>I</sup>		72	87 <sup>8</sup>	8			94	100 <sup>8</sup>				100									100	100	100
<i>Klebsiella pneumoniae</i>	87		0 <sup>I</sup>		88	87 <sup>8</sup>	78			90	98 <sup>8</sup>				96									88	85	85
<i>Proteus mirabilis</i>	33		90		100	100 <sup>8</sup>	21			96	100 <sup>8</sup>				93						0 <sup>I</sup>			90	90	90
<i>Pseudomonas aeruginosa</i>	183		0 <sup>I</sup>		0 <sup>I</sup>	80			86	0 <sup>I</sup>	90	91									0 <sup>I</sup>			0 <sup>I</sup>	89	86
<i>Serratia marcescens</i>	48		0 <sup>I</sup>		0 <sup>I</sup>		0 <sup>I</sup>			100	100 <sup>8</sup>				100									100	95	95
<i>Stenotrophomonas maltophilia</i>	34		0 <sup>I</sup>		0 <sup>I</sup>	0 <sup>I</sup>				0 <sup>I</sup>		0 <sup>I</sup>			0 <sup>I</sup>	0 <sup>I</sup>								0 <sup>IS</sup>	94 <sup>11</sup>	91 <sup>12</sup>
<i>Bacteroides fragilis</i> group	41 <sup>15</sup>				93 <sup>15</sup>															100 <sup>13</sup>						91 <sup>12</sup>

<sup>1</sup> MRSA rate = 35% of all *Staphylococcus aureus* isolates from DH inpatient (MHMH/APD/NLH) non-urine sources.

<sup>2</sup> Daptomycin: *Staphylococcus aureus* ALL n=39, *Staphylococcus aureus* MRSA n=35.

<sup>3</sup> Gentamicin should not be used for monotherapy for gram-positive bacteria.

<sup>4</sup> Coagulase-negative *Staphylococcus* and Tetracycline: n=96.

<sup>5</sup> *Enterococcus faecium* & Daptomycin: n=30. All isolates tested susceptible-dose dependent (SDD) which requires daptomycin doses of 10-12 mg/kg/day.

<sup>6</sup> Synergy is predicted for therapy with penicillin, ampicillin, or vancomycin combined with gentamicin.

<sup>7</sup> Susceptibility to ampicillin is based on a negative beta-lactamase test result.

<sup>8</sup> Percentage accounts for isolates that test S + SDD. Less than 5% of isolates tested SDD for each bug-drug combination.

<sup>9</sup> Ceftriaxone and *E. cloacae* complex; n=49.

<sup>10</sup> Percentage accounts for isolates that test S + SDD. 9% of isolates tested SDD for *E. cloacae* complex and cefepime.

<sup>11</sup> Use high dose minocycline 200mg IV/PO Q12h, when used to treat *Stenotrophomonas maltophilia*.

<sup>12</sup> *S. maltophilia* - Trimethoprim-sulfamethoxazole and levofloxacin should not be used alone for antimicrobial therapy.

<sup>13</sup> *B. fragilis* group: 2024 & 2025 data combined.

<sup>14</sup> Intrinsic resistance.

<sup>15</sup> *S. maltophilia* is intrinsically resistant to tetracycline, but not to doxycycline, minocycline or tigecycline.

For use by providers within the DH system only. Please do not share with pharmaceutical representatives.